• Citer

Pimasertib versus dacarbazine in patients with unresectable NRAS-mutated cutaneous melanoma: Phase II, randomized, controlled trial with crossover

par Lebbe, Céleste;Dutriaux, Caroline;Lesimple, Thierry;Kruit, Wim H;Kerger, Joseph ;Thomas, Luc;Guillot, Bernard;De Braud, Filippo De;Garbe, Claus;Grob, Jean Jacques;Loquai, Carmen;Ferraresi, Virginia;Robert, Caroline;Vasey, Paul;Conry, Robert;Isaacs, Richard;Espinosa, Enrique;Schueler, Armin;Massimini, Giorgio;Dreno, Brigitte
Référence Cancers (Basel), 12, 7, page (1-11), 1727
Publication Publié, 2020-07

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Pimasertib versus dacarbazine in patients with unresectable NRAS-mutated cutaneous melanoma: Phase II, randomized, controlled trial with crossover
Auteur:	Lebbe, Céleste; Dutriaux, Caroline; Lesimple, Thierry; Kruit, Wim H; Kerger, Joseph; Thomas, Luc; Guillot, Bernard; De Braud, Filippo De; Garbe, Claus; Grob, Jean Jacques; Loquai, Carmen; Ferraresi, Virginia; Robert, Caroline; Vasey, Paul; Conry, Robert; Isaacs, Richard; Espinosa, Enrique; Schueler, Armin; Massimini, Giorgio; Dreno, Brigitte
Informations sur la publication:	Cancers (Basel), 12, 7, page (1-11), 1727
Statut de publication:	Publié, 2020-07
Sujet CREF:	Cancérologie
	Sciences bio-médicales et agricoles
Mots-clés:	Adverse events
	Dacarbazine
	Malignant melanoma
	N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
	Pimasertib
	Progression-free survival
	Quality of life
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2072-6694
	info:doi/10.3390/cancers12071727
	info:scp/85087132347